Minoryx has raised €21.3 million in series B funding. The round sets Minoryx up to expand clinical development of a neurodegenerative disease drug that has attracted the interest of organizations including Roche Venture Fund.
Teva Pharm`s Generic Rosiglitazone Maleate; Glimepiride approved in US as an antidiabetic drugs
FDA Warns vs 20 Unregistered Drugs
Market Place
Share
Share
